Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net loss	$ (35,410)	$ (22,917)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	33	29
Stock-based compensation expense	4,954	2,911
Amortization of premiums and accretion of discounts on marketable securities, net	(3,222)	(634)
Change in fair value of embedded derivatives	(1,050)	0
Amortization of right-of-use asset	56	76
Realized gain on marketable securities	(2)	0
Non-cash interest expense	539	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(3,350)	(1,933)
Other assets	(7)	(57)
Accounts payable	2,823	384
Accrued clinical trial expenses	2,640	1,385
Accrued expenses and other current liabilities	(2,335)	(1,013)
Finance lease liability	(23)	0
Operating lease liability	(50)	(76)
Net cash used in operating activities	(34,404)	(21,845)
Cash flows from investing activities
Purchases of marketable securities	(57,093)	(52,131)
Proceeds from maturities and sales of marketable securities	85,605	21,268
Purchases of property and equipment	(16)	0
Net cash provided by (used in) investing activities	28,496	(30,863)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	7,938	0
Payment for financing lease	(739)	0
Payments for deferred offering costs	(188)	(145)
Repurchase of common shares to pay employee withholding taxes	(32)	0
Net cash provided by (used in) financing activities	6,979	(145)
Net change in cash and cash equivalents and restricted cash	1,071	(52,853)
Cash and cash equivalents and restricted cash at the beginning of the period	67,119	130,101
Cash and cash equivalents and restricted cash at the end of the period	68,190	77,248
Supplemental disclosure of cash flow information
Cash paid for income taxes	0	0
Cash paid for interest	1,496	0
Supplemental disclosure of noncash investing and financing activities
Deferred offering costs in accounts payable	9	2
Deferred offering costs in accrued expenses and other current liabilities	$ 0	$ 36